|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����Ī˾ |
|
���� |
|
ҩ���Ʒ� |
| ��������������� | |
|
���� |
|
������ |
| PubMed | |
|
Article by LIN Xiao |
|
Article by FU Wen-wen |
Ƥ����������Ī˾���ư���
����, ������
������ѧ������ɽҽԺƤ����, �Ϻ� 200040
����Ī˾��һ��ǿЧ���������������Ƽ�,�����������Ƽ��IJ���,Խ��Խ�㷺������Ƥ����������,����������Ӧ��Ƥ���ѽ�Ϊ����.�ڰ����������Ҳȡ����һ���ij�Ч,��������ֲ�������ӦС,�����Ը�,�нϺõ�Ӧ��ǰ��,����ȱ�������˫ä�����յ��ٴ�����,����Ī˾�ڰ����������뼲�����͵Ĺ�ϵ,�Ƿ�����δ���ֵIJ�����Ӧ������ʹ��ϵͳ�����Ƿ���ȫ������Ӧ,��������һ�����о�.
Therapeutic Effect of Topical Taerolimus in Vitiligo Treatment
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
Tacrolimus is a potent macrolide immunosupressant.With the development of topical preparation of tacrolimus,it is widely used in the treatment of skin diseases,and has been successfully used in atopic dermatitis.Also,because of its safety and high tolerance,it is expected to be used in vitiligo treatment.Since lack of randomized,double-blind and controlled clinical trials,large sample research is still required to investigate the relationship between the drug and clinical types of vitiligo,potential adverse reaction,systemic side effects due to long-term treatment,etc.
[2] Caixia T,Hongwen F,Xiran L.Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo.J Dermatol Sci,1999,21:59-62.
[3] Wang X,Erf GF.Apoptosis in feathers of Smyth line chickens with autoimmune vitiligo.J Autoimmun,2004,22:21-30.
[4] Wang X,Erf GF.Melanocyte-specific cell mediated immune response in vitiliginous Smyth line chickens.J Autoimmun,2003,21:149-160.
[5] Austin LM,Boissy RE.Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens.An avian model for human vitiligo.Am J Pathol,1995,146:1529-1541.
[6] Ruzicka T,Assmann T,Homey B.Tacrolimus:the drug for the turn of the millennium? Arch Dermatol,1999,135:574-580.
[7] Marsland AM,Griffiths CE.The macrolide immunosuppressants in dermatology:mechanisms of action.Eur J Dermatol,2002,12:618-622.
[8] Cheer SM,Plosker GL.Tacrolimus ointment.A review of its therapeutic potential as a topical therapy in atopic dermatitis.Am J Clin Dermatol,2001,2:389-406.
[9] Nghiem P,Pearson G,Langley RG.Tacrolimus and pimecrolimus:from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.J Am Acad Dermatol,2002,46:228-241.
[10] Wollenberg A,Sharma S,von BubnoffD,et al.Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis.J Allergy Clin Immunol,2001,107:519-525.
[11] Lan CC,Chen GS,Chiou MH,et al.FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes:possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.Br J Dermatol,2005,153:498-505.
[12] Smith DA,Tofte SJ,Hanifin JM.Repigmentation ofvitiligo with topical tacrolimus.Dermatology,2002,205:301-303.
[13] Grimes PE,Soriano T,Dytoc MT.Topical tacrolimus for repigmentation of vitiligo.J Am Acad Dermatol,2002,47:789-791.
[14] Tanghetti EA.Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo:results of a prospective patient series.Cutis,2003,71:158-162.
[15] Travis LB,Weinberg JM,Silverberg NB.Successful treatment ofvitiligo with 0.1% tacrolimus ointment.Arch Dermatol,2003,139:571-4;discussion 573.
[16] Passeron T,Ostovari N,Zakaria W,et al.Topical tacrolimus and the 308-nm excimer laser:a synergistic combination for the treatment of vitiligo.Arch Dermatol,2004,140:1065-1069.
[17] Kanwar AJ,Dogra S,Parsad D.Topical tacrolimus for treatment of childhood vitiligo in Asians.Clin Exp Dermatol,2004,29:589-592.
[18] Lepe V,Moncada B,Castanedo-Cazares JP,et al.A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.Arch Dermatol,2003,139:581-585.
[19] Silverberg NB,Lin P,Travis L,et al.Tacrolimus ointment promotes repigmentation of vitiligo in children:a review of 57 cases.J Am Acad Dermatol,2004,51:760-766.
[20] Reitamo S,Rissanen J,Remitz A,et al.Tacrolimus ointment does not affect collagen synthesis:results of a single-center randomized trial.J Invest Dermatol,1998,111:396-398.